Abstract
Montelukast sodium (Singulair, Merck and Co., Inc., Whitehouse Station, NJ) is a selective and orally-active leukotriene receptor antagonist with demonstrated effectiveness for treating allergic asthma and allergic rhinitis in adults and children as young as 12 months of age for allergic asthma and 6 months of age for allergic rhinitis. It was recently approved in the US for prevention of exercise-induced bronchoconstriction in patients who are > or = 15 years of age. This paper updates a prior review of the data on the clinical efficacy of montelukast published in this journal.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acetates / therapeutic use*
-
Animals
-
Anti-Asthmatic Agents / administration & dosage
-
Anti-Asthmatic Agents / therapeutic use
-
Asthma / drug therapy*
-
Asthma, Exercise-Induced / drug therapy
-
Bronchoconstriction / drug effects*
-
Cyclopropanes
-
Humans
-
Leukotriene Antagonists / administration & dosage
-
Leukotriene Antagonists / therapeutic use
-
Quinolines / therapeutic use*
-
Rhinitis, Allergic, Perennial / drug therapy*
-
Rhinitis, Allergic, Seasonal / drug therapy*
-
Sulfides
Substances
-
Acetates
-
Anti-Asthmatic Agents
-
Cyclopropanes
-
Leukotriene Antagonists
-
Quinolines
-
Sulfides
-
montelukast